PubMed · 10191781
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M Wachtel. 1999. Estimating interobserver reliability.. https://doi.org/10.1093/ajcp%2F111.4.567
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
There is an evidence to suggest that cdc25B phosphatase is an oncogenic. We hypothesized that cdc25B gene may be expressed in tumors of patients with non-small cell lung cancer (NSCLC) and affect their clinical outcome. Expression of cdc25B messenger RNA was evaluated by reverse transcription polymerase chain reaction in 55 non-small cell lung carcinomas and adjacent histological normal lung samples using LightCycler. The data was analyzed in reference to clinicopathological data and survival data. There was no difference of cdc25B expression level between the NSCLC tissue and normal lung tissue. There was no relationship between cdc25B gene expression and age, gender, N or T-status and clinical stage. However, the NSCLC patients with high cdc25B expression had significantly poor survival than the patients with low cdc25B expression (P=0.0173). Thus we suggest that cdc25B may predict poor survival.
Hormone-related cancers in the prostate, breast, endometrium, ovary and testicle account for 30% of malignancies in humans. We have developed a unique model of spontaneous prostate cancer (PC) in Lobund-Wistar [L-W] rats that shares many of its characteristics with the natural history of PC in man, including (a) inherent predisposition, high production of testosterone and aging risk factors, (b) endogenous tumorigenic mechanisms, and (c) early stage testosterone-dependent and late stage testosterone-independent tumors. About 30% of L-W rats on diet L-485 develop spontaneous palpable cancer in the anterior prostate-seminal vesicle (P-SV) complex in average of 20.5 months. At age 12 months early stage spontaneous PC was prevented or reversed by testosterone-deprivation through change of diet from L-485 to soy protein isolate/isoflavone (SPII) diet, thereby preventing the late lethal clinical disease: about 75% of rats at risk of developing testosterone-independent P-SV tumors were free of detectable cancer and about 25% had developed testosterone-independent cancer at age 12 months. The duration of the dependent stage exceeded age 12 months in 75% of the rats at risk. Dietary soymeal, found in most natural ingredient diets, may promote PC tumorigenesis, but only in L-W rats.
PURPOSE: To evaluate the inguinal nodal failure rate in patients with locally advanced rectal cancer with anal canal involvement (ACI) treated with pelvic chemoradiation without elective inguinal irradiation. METHODS AND MATERIALS: From 1990 and 1998, 536 patients received preoperative or postoperative chemoradiation for rectal cancer with curative intent; 186 patients had ACI (<4 cm from the anal verge on rigid proctoscopy). Two patients had positive inguinal nodes at presentation. Chemoradiation was delivered preoperatively (45 Gy in 25 fraction) or postoperatively (53 Gy in 29 fractions) with concurrent continuous infusion of 5-fluorouracil (300 mg/m2/d). The inguinal region was specifically irradiated in only 2 patients who had documented inguinal nodal disease. RESULTS: The median follow-up was 50 months. Only 6 of 184 ACI patients who had clinically negative inguinal nodes at presentation developed inguinal nodal recurrence (5-year actuarial rate 4%); 4 of the 6 cases were isolated. Two patients underwent successful salvage. Only 1 died of uncontrolled groin disease. Local control was achieved in both patients with inguinal nodal disease at presentation, but both died of metastatic disease. Only 3 patients with tumors >4 cm from the verge developed inguinal recurrence (5-year actuarial rate <1%). CONCLUSIONS: Inguinal nodal failure in rectal cancer patients with ACI treated with neoadjuvant or adjuvant chemoradiation is not high enough to justify routine elective groin irradiation.